WASHINGTON — Sen. Chuck Grassley on Monday accused Democrats of walking away from negotiations on a bill meant to lower prescription drug prices — a bill that has, until now, enjoyed more support from Democrats in the Senate than from most Republicans in the chamber.
The Iowa Republican’s surprisingly public airing of grievances, in a Wall Street Journal op-ed, is the latest indication that Congress is unlikely to pass meaningful pharmaceutical industry reforms before November’s election.
Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!
GET STARTEDWhat is it?
STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.
What's included?
- Daily reporting and analysis
- The most comprehensive industry coverage from a powerhouse team of reporters
- Subscriber-only newsletters
- Daily newsletters to brief you on the most important industry news of the day
- STAT+ Conversations
- Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
- Exclusive industry events
- Premium access to subscriber-only networking events around the country
- The best reporters in the industry
- The most trusted and well-connected newsroom in the health care industry
- And much more
- Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
About the Author Reprints
Looks to me as though PCMA got to both parties. It’s amazing how a little gelt
makes nothing happen.